Sagimet Biosciences Inc.(SGMT)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .

Sagimet Biosciences Inc. (SGMT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. SGMT is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $2.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of SGMT by reported 13-F value include BlackRock, BALYASNY ASSET MANAGEMENT L.P., Woodline Partners, based on the most recent SEC filings. SGMT trades on the Nasdaq exchange and files with the SEC under CIK 1400118. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SGMT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Sagimet Biosciences Inc. directly from SEC EDGAR.

Net Income

$-14.0M

SGMT key financials by period

Sagimet Biosciences Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodFormRevenueNet incomeOperating margin
FY 202310-K$2.0M$-27.9M—

Institutions holding SGMT

Institutional investors reporting a position in Sagimet Biosciences Inc. on SEC Form 13F.
InstitutionSharesValueReported
BlackRock6,575,788$50.8M2026-06-30
BALYASNY ASSET MANAGEMENT L.P.3,626,113$28.0M2026-06-30
Woodline Partners3,000,652$23.2M2026-06-30
SILVERARC CAPITAL MANAGEMENT2,927,698$22.6M2026-06-30
VANGUARD CAPITAL MANAGEMENT2,566,272$19.8M2026-06-30
BVF2,500,000$19.3M2026-06-30
Caligan Partners2,500,000$19.3M2026-06-30
Affinity Asset Advisors2,497,864$19.3M2026-06-30
FEDERATED HERMES2,086,715$16.1M2026-06-30
GREAT POINT PARTNERS2,029,933$15.7M2026-06-30
SEC EDGAR: CIK 1400118 →
SGMT

Sagimet Biosciences Inc.

SGMT
NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $2.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Price Chart

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.
Reading the latest SEC filing… (first load can take ~20s)

Key Metrics

Net Income

Q2 2026
EDGAR

$-13.95M

EPS (Diluted)

Q2 2026
EDGAR

$-0.26

ROIC

Q2 2026
EDGAR

-24.7%

Top Institutional Holders

as of Q2 2026
$401.24M total
BlackRock, Inc.
$50.83M+722.0%
BALYASNY ASSET MANAGEMENT L.P.
$28.03MNew
Woodline Partners LP
$23.20M+199.8%
SILVERARC CAPITAL MANAGEMENT, LLC
$22.63MNew
VANGUARD CAPITAL MANAGEMENT LLC
$19.84M+133.5%
BVF INC/IL
$19.32MNew
Caligan Partners LP
$19.32MNew
Affinity Asset Advisors, LLC
$19.31M+187.8%
FEDERATED HERMES, INC.
$16.13MNew
GREAT POINT PARTNERS LLC
$15.69MNew

Financial Trends

Revenue & Net Income

Earnings Per Share

Loading ratio trend…